Form 8-K Crinetics Pharmaceutical For: Mar 19
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Crinetics (CRNX) PT Raised to $56 at Jones Trading
March 19, 2024 1:30 PM EDTJones Trading analyst Catherine Novack raised the price target on Crinetics (NASDAQ: CRNX) to $56.00 (from $52.00) while maintaining a Buy rating.
The analyst comments "Crinetics reported topline Phase 3 PATHFNDR-2 data in acromegaly ( press release ). The data are an unambiguous win, and in... More
